Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into in the Clinic

Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, today announced the publication of a manuscript in the peer reviewed journal Stroke entitled: Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. The manuscript describes the results of pre-clinical studies using AST-004, Astrocyte’s lead drug candidate, for the treatment of stroke. Read more >>